Shortly before Regeneron Pharmaceuticals won the right last year to sell a new drug for severe eczema, the company’s chief executive promised to price the medicine “responsibly” in order to avoid the anger over high drug prices. At first blush, he appeared to have succeeded – the $37,000 price tag for Dupixent was in line with an evaluation by a closely followed cost-effectiveness watchdog.

But a year later, the effort has not produced all of the desired results. Regeneron has, indeed, escaped public criticism for its pricing, which is something of a moral victory for Dr. Len Schleifer, the outspoken chief executive. However, a majority of physicians report that access to the medicine is still being “tightly controlled and restricted” by payers, according to a newly released survey of dermatologists by Leerink analysts.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy